Marshall Edwards shares crash on PhIII cancer failure

Shares of Marshall Edwards (NASDAQ: MSHL) plummeted yesterday evening after the developer reported that its therapy for ovarian cancer--phenoxodiol--had failed to hit key endpoints in a late-stage trial. Australia's Novogen licensed the drug to Marshall Edwards, which it also holds a majority interest in. Researchers reported that the oral formulation of their drug failed to achieve the kind of progression-free survival or overall survival results they needed to ace the...